|
1
|
Bahner JD and Bordeaux JS: Non-melanoma
skin cancers: Photodynamic therapy, cryotherapy, 5-fluorouracil,
imiquimod, diclofenac, or what? Facts and controversies. Clin
Dermatol. 31:792–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Madan V, Lear JT and Szeimies RM:
Non-melanoma skin cancer. Lancet. 375:673–685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christenson LJ, Borrowman TA, Vachon CM,
Tollefson MM, Otley CC, Weaver AL and Roenigk RK: Incidence of
basal cell and squamous cell carcinomas in a population younger
than 40 years. JAMA. 294:681–690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dummer R, Karpova MB and Barysch MJ: Basal
cell carcinomas: Molecular abnormalities and molecularly targeted
therapies. Expert Rev Dermatol. 4:355–369. 2009. View Article : Google Scholar
|
|
5
|
Rippey JJ: Why classify basal cell
carcinomas? Histopathology. 32:393–398. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rubin AI, Chen EH and Ratner D: Basal-cell
carcinoma. N Engl J Med. 353:2262–2269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akira S and Hemmi H: Recognition of
pathogen associated molecular patterns by TLR family. Immunol Lett.
85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyake K: Innate immune sensing of
pathogens and danger signals by cell surface Toll-like receptors.
Semin Immunol. 19:3–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iwasaki A and Medzhitov R: Toll-like
receptor control of the adaptive immune responses. Nat Immunol.
5:987–995. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Medzhitov R: Toll-like receptors and
innate immunity. Nat Rev Immunol. 1:135–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burns EM and Yusuf N: Toll-like receptors
and skin cancer. Front Immunol. 5:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kutikhin AG: Association of polymorphisms
in TLR genes and in genes of the Toll-like receptor signaling
pathway with cancer risk. Hum Immunol. 72:1095–1116. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basith S, Manavalan B, Yoo TH, Kim SG and
Choi S: Roles of Toll-like receptors in cancer: A double-edged
sword for defense and offense. Arch Pharm Res. 35:1297–1316. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eiró N, Ovies C, Fernandez-Garcia B,
Álvarez-Cuesta CC, González L, González LO and Vizoso FJ:
Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma:
Relationship with clinicopathological characteristics and
prognosis. Arch Dermatol Res. 305:59–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ermertcan AT, Öztürk F and Gündüz K:
Toll-like receptors and skin. J Eur Acad Dermatol Venereol.
25:997–1006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diebold SS, Kaisho T, Hemmi H, Akira S and
Reise Sousa C: Innate antiviral responses by means of TLR7-mediated
recognition of single-stranded RNA. Science. 303:1529–1531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta AK, Cherman AM and Tyring SK: Viral
and nonviral uses of imiquimod: A review. J Cutan Med Surg.
8:338–352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tyring S, Conant M, Marini M, Van Der
Meijden W and Washenik K: Imiquimod; an international update on
therapeutic uses in dermatology. Int J Dermatol. 41:810–816. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tengroth L, Millrud CR, Kvarnhammar AM,
Kumlien Georén S, Latif L and Cardell LO: Functional effects of
Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in
nasal epithelial cells. PLoS One. 9:e982392014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Yang H, Barnie PA, Yang P, Su Z,
Chen J, Jiao Z, Lu L, Wang S and Xu H: The expression of Toll-like
receptor 8 and its relationship with VEGF and Bcl-2 in cervical
cancer. Int J Med Sci. 11:608–613. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
zur Hausen H: Condylomata acuminata and
human genital cancer. Cancer Res. 36:7941976.PubMed/NCBI
|
|
22
|
Parsonnet J, Friedman GD, Vandersteen DP,
Chang Y, Vogelman JH, Orentreich N and Sibley RK: Helicobacter
pylori infection and the risk of gastric carcinoma. N Engl J
Med. 325:1127–1131. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bargen JA: Chronic ulcerative colitis
associated with malignant disease. 1928. Dis Colon Rectum.
37:727–730. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beasley RP, Hwang LY, Lin CC and Chien CS:
Hepatocellular carcinoma and hepatitis B virus. A prospective study
of 22707 men in Taiwan. Lancet. 2:1129–1133. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang B, Zhao J, Li H, He KL, Chen Y, Chen
SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor
cells facilitate evasion of immune surveillance. Cancer Res.
65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmausser B, Andrulis M, Endrich S,
Müller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and
TLR9 on gastric carcinoma cells: An implication for interaction
with Helicobacter pylori. Int J Med Microbiol. 295:179–185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Droemann D, Albrecht D, Gerdes J, Ulmer
AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Helminen O, Huhta H, Takala H, Lehenkari
PP, Saarnio J, Kauppila JH and Karttunen TJ: Increased Toll-like
receptor 5 expression indicates esophageal columnar dysplasia.
Virchows Arch. 464:11–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jouhi L, Renkonen S, Atula T, Mäkitie A,
Haglund C and Hagström J: Different Toll-like receptor expression
patterns in progression toward cancer. Front Immunol. 5:6382014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fukata M, Chen A, Vamadevan AS, Cohen J,
Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, et
al: Toll-like receptor-4 promotes the development of
colitis-associated colorectal tumors. Gastroenterology.
133:1869–1881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okamoto M, Oshikawa T, Tano T, Ohe G,
Furuichi S, Nishikawa H, Ahmed SU, Akashi S, Miyake K, Takeuchi O,
et al: Involvement of Toll-like receptor 4 signaling in
interferon-gamma production and antitumor effect by streptococcal
agent OK-432. J Natl Cancer Inst. 95:316–326. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lowe EL, Crother TR, Rabizadeh S, Hu B,
Wang H, Chen S, Shimada K, Wong MH, Michelsen KS and Arditi M:
Toll-like receptor 2 signaling protects mice from tumor development
in a mouse model of colitis-induced cancer. PLoS One. 5:e130272010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Matijevic T, Marjanovic M and Pavelic J:
Functionally active Toll-like receptor 3 on human primary and
metastatic cancer cells. Scand J Immunol. 70:18–24. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bauer AK, Dixon D, DeGraff LM, Cho HY,
Walker CR, Malkinson AM and Kleeberger SR: Toll-like receptor 4 in
butylated hydroxytoluene-induced mouse pulmonary inflammation and
tumorigenesis. J Natl Cancer Inst. 97:1778–1781. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Krieg AM: Antitumor applications of
stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides.
Curr Oncol Rep. 6:88–95. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aspord C, Tramcourt L, Leloup C, Molens
JP, Leccia MT, Charles J and Plumas J: Imiquimod inhibits melanoma
development by promoting pDC cytotoxic functions and impeding tumor
vascularization. J Invest Dermatol. 134:2551–2561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang J, Kobayashi M, Han M, Choi S, Takano
M, Hashino S, Tanaka J, Kondoh T, Kawamura K and Hosokawa M: MyD88
is involved in the signalling pathway for Taxol-induced apoptosis
and TNF-alpha expression in human myelomonocytic cells. Br J
Haematol. 118:638–645. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schiaffo CE, Shi C, Xiong Z, Olin M,
Ohlfest JR, Aldrich CC and Ferguson DM: Structure-activity
relationship analysis of imidazoquinolines with Toll-like receptors
7 and 8 selectivity and enhanced cytokine induction. J Med Chem.
57:339–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Takeda K and Akira S: Toll-like receptors
in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schön M and Schön MP: The antitumoral mode
of action of imiquimod and other imidazoquinolines. Curr Med Chem.
14:681–687. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Quirk C, Gebauer K, De'Ambrosis B, Slade
HB and Meng TC: Sustained clearance of superficial basal cell
carcinomas treated with imiquimod cream 5%: Results of a
prospective 5-year study. Cutis. 85:318–324. 2010.PubMed/NCBI
|
|
43
|
Alessi SS, Sanches JA, Oliveira WR,
Messina MC, Pimentel ER and Festa Neto C: Treatment of cutaneous
tumors with topical 5% imiquimod cream. Clinics (Sao Paulo).
64:961–966. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ruiz-Villaverde R, Sánchez-Cano D and
Burkhardt-Pérez P: Superficial basal cell carcinoma treated with
imiquimod 5% topical cream for a 4-week period: A case series. J
Eur Acad Dermatol Venereol. 23:828–831. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gollnick H, Barona CG, Frank RG, Ruzicka
T, Megahed M, Maus J and Munzel U: Recurrence rate of superficial
basal cell carcinoma following treatment with imiquimod 5% cream:
Conclusion of a 5-year long-term follow-up study in Europe. Eur J
Dermatol. 18:677–682. 2008.PubMed/NCBI
|
|
46
|
Sterry W, Ruzicka T, Herrera E, Takwale A,
Bichel J, Andres K, Ding L and Thissen MR: Imiquimod 5% cream for
the treatment of superficial and nodular basal cell carcinoma:
Randomized studies comparing low-frequency dosing with and without
occlusion. Br J Dermatol. 147:1227–1236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Valins W, Amini S and Berman B: The
expression of Toll-like receptors in dermatological diseases and
the therapeutic effect of current and newer topical Toll-like
receptor modulators. J Clin Aesthet Dermatol. 3:20–29.
2010.PubMed/NCBI
|
|
48
|
Askar E, Ramadori G and Mihm S: Toll-like
receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C
virus infection. J Med Virol. 82:1859–1868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang R, Town T, Gokarn V, Flavell RA and
Chandawarkar RY: HSP70 enhances macrophage phagocytosis by
interaction with lipid raft-associated TLR-7 and upregulating p38
MAPK and PI3K pathways. J Surg Res. 136:58–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen X, Liang H, Zhang J, Zen K and Zhang
CY: MicroRNAs are ligands of Toll-like receptors. RNA. 19:737–739.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Calapre L, Gray ES and Ziman M: Heat
stress: A risk factor for skin carcinogenesis. Cancer Lett.
337:35–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Syed DN, Khan MI, Shabbir M and Mukhtar H:
MicroRNAs in skin response to UV radiation. Curr Drug Targets.
14:1128–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
